Last update July 1, 2015

Orphenadrine Citrate

Low Risk

Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

Anti-muscarinic analogue agent similar to Diphenhydramine with no sedative effect. Used for the treatment of muscle spasms and Parkinson Disease.

At latest update, relevant published data on excretion into breast milk were not found.

Its pharmacokinetics (moderately high molecular weight and high protein-binding capacity) makes excretion into breast milk in significant amount be unlikely.

Until more data on this medication is available, safer alternative drugs are preferred especially in premature babies or during the neonatal period.

Whenever used while breastfeeding take the lowest dose as possible along with a follow-up for somnolence and troubles of the infant with feeding.

It is not commercially available in Spain.

Alternatives

  • Baclofen ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Methocarbamol (Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Orphenadrine Citrate is also known as Orphenadrine. Here it is a list of alternative known names::


Orphenadrine Citrate in other languages or writings:

Groups

Orphenadrine Citrate belongs to these groups or families:

Tradenames

Main tradenames from several countries containing Orphenadrine Citrate in its composition:

List of 10 tradenames

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 90 %
Molecular weight 462 daltons
Protein Binding 95 %
Tmax 2 - 4 hours
T½ 16 - 31 hours

References

  1. eMC. Orphenadrine. Drug Summary. 2013 Full text (in our servers)
  2. Rosemont Pharmaceuticals Ltd. Orphenadrine. Drug Summary. 2013 Full text (in our servers)
  3. Farmical. Orfenadrina. Ficha técnica. 2010 Full text (in our servers)
  4. Lee SY, Oh HJ, Kim JW, Kim YG, Moon CJ, Lee EH. Pharmacokinetic study of orphenadrine using high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Abstract
  5. Labout JJ, Thijssen Ct, Keijser GG, Hespe W. Difference between single and multiple dose pharmacokinetics of orphenadrine hydrochloride in man. Eur J Clin Pharmacol. 1982 Abstract

Total visits

32,499

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2006 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM